Skip to main content

Table 1 Baseline characteristics in the entire cohort and in patients with low and high UPCR

From: Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)

 

Total

(n = 60)

Low UPCR

(n = 36)

High UPCR

(n = 24)

P*

Mean age, years (range)

67.4 (36–86)

67.2 (36–86)

67.8 (46–82)

0.958

Male, n(%)

38 (63.3)

22 (61.1)

16 (66.7)

0.66

Mean body weight, Kg (range)

57.5 (32.7–101)

54.5 (32.7–81.5)

62.0 (44.4–101)

0.036

ECOG PS, n(%)

   

0.831

 0

43 (72)

25 (69)

18 (75)

 

 1

11 (18)

7 (19)

4 (17)

 

 2

2 (3)

2 (6)

0

 

 unknown

4 (7)

2 (6)

2 (8)

 

Primary Site

   

0.50

 Gastric cancer

11 (18)

8 (22)

3 (13)

 

 Colorectal cancer

49 (82)

28 (78)

21 (88)

 

Pathological status

   

1

 tub1/tub2

47 (78)

28 (78)

19 (79)

 

 others

13 (22)

8 (22)

5 (21)

 

Used anti-VEGF/Ri

   

1

 Bevacizumab

41 (68)

25 (69)

16 (67)

 

 Ramucirumab

17 (28)

10 (28)

7 (29)

 

 Aflibercept

2 (3)

1 (3)

1 (4)

 

RAS inhibitor usage

   

0.06

 YES

17 (28)

7 (19)

10 (42)

 

 NO

43 (72)

29 (81)

14 (58)

 

Prior anti-VEGF/Ri usage

   

0.65

 YES

18 (30)

10 (28)

8 (33)

 

 NO

42 (70)

26 (72)

16 (67)

 

Onset QV status (%)

   

0.013

 2+

53 (88)

35 (97)

18 (75)

 

 3+ or more

7 (12)

1 (3)

6 (25)

 

Worst QV status

   

< 0.001

 2+

34 (57)

30 (83)

4 (17)

 

 3+ or more

26 (43)

6 (17)

20 (83)

 
  1. *Fisher’s exact test
  2. Abbreviations: anti-VEGF/Ri anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors, ECOG PS Eastern Cooperative Oncology Group Performance Status Scale, UPCR a single urine protein/creatinine ratio, QV a qualitative value test